[go: up one dir, main page]

WO2004063709A8 - Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators - Google Patents

Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Info

Publication number
WO2004063709A8
WO2004063709A8 PCT/US2004/000368 US2004000368W WO2004063709A8 WO 2004063709 A8 WO2004063709 A8 WO 2004063709A8 US 2004000368 W US2004000368 W US 2004000368W WO 2004063709 A8 WO2004063709 A8 WO 2004063709A8
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
methods
growth factor
mammal
factor receptor
Prior art date
Application number
PCT/US2004/000368
Other languages
French (fr)
Other versions
WO2004063709A2 (en
WO2004063709A3 (en
Inventor
Lukas C Amler
Thomas Januario
Original Assignee
Bristol Myers Squibb Co
Lukas C Amler
Thomas Januario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Lukas C Amler, Thomas Januario filed Critical Bristol Myers Squibb Co
Priority to CA002512536A priority Critical patent/CA2512536A1/en
Priority to US10/541,749 priority patent/US20060234237A1/en
Priority to EP04700860A priority patent/EP1597558A2/en
Priority to JP2006500841A priority patent/JP2007520995A/en
Publication of WO2004063709A2 publication Critical patent/WO2004063709A2/en
Publication of WO2004063709A8 publication Critical patent/WO2004063709A8/en
Publication of WO2004063709A3 publication Critical patent/WO2004063709A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

EGFR biomakers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing the mammal to the EGFR modulator and (b) measuring in the mammal level of at least one biomaker, wherein a difference in the level in at least one biomaker measured in (b) compared to the level of the biomaker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.
PCT/US2004/000368 2003-01-08 2004-01-08 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators WO2004063709A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002512536A CA2512536A1 (en) 2003-01-08 2004-01-08 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US10/541,749 US20060234237A1 (en) 2004-01-08 2004-01-08 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
EP04700860A EP1597558A2 (en) 2003-01-08 2004-01-08 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
JP2006500841A JP2007520995A (en) 2003-01-08 2004-01-08 Biomarkers and methods for determining susceptibility to epidermal growth factor receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43873503P 2003-01-08 2003-01-08
US60/438,735 2003-01-08

Publications (3)

Publication Number Publication Date
WO2004063709A2 WO2004063709A2 (en) 2004-07-29
WO2004063709A8 true WO2004063709A8 (en) 2005-03-31
WO2004063709A3 WO2004063709A3 (en) 2008-05-15

Family

ID=32713370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000368 WO2004063709A2 (en) 2003-01-08 2004-01-08 Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Country Status (4)

Country Link
EP (1) EP1597558A2 (en)
JP (1) JP2007520995A (en)
CA (1) CA2512536A1 (en)
WO (1) WO2004063709A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
EP1751309B1 (en) 2004-05-27 2015-07-22 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101141981A (en) 2005-01-21 2008-03-12 健泰科生物技术公司 Fixed dosing of her antibodies
EP3195879A1 (en) 2005-02-23 2017-07-26 Genentech, Inc. Extending time to disease progression or survival in cancer patients
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
AR053272A1 (en) 2005-05-11 2007-04-25 Hoffmann La Roche DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY
ES2370054T3 (en) 2005-08-24 2011-12-12 Bristol-Myers Squibb Company BIOMARKERS AND PROCEDURES TO DETERMINE THE SENSITIVITY TO MODULATORS OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR.
DK1926996T3 (en) 2005-09-20 2012-01-23 Osi Pharmaceuticals Llc Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
JP5240739B2 (en) 2007-04-13 2013-07-17 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Biological markers that predict anticancer responses to kinase inhibitors
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009002175A1 (en) * 2007-06-28 2008-12-31 Agendia B.V. A method of typing a sample comprising colorectal cancer cells
EP2201378A2 (en) 2007-10-03 2010-06-30 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045389A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
AU2010268690B2 (en) 2009-07-03 2011-11-10 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
JP2013527748A (en) 2010-03-03 2013-07-04 オーエスアイ・ファーマシューティカルズ，エルエルシー Biological markers useful for predicting anticancer responses to insulin-like growth factor 1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
PT2528625E (en) 2010-04-15 2013-10-17 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN103068406B (en) 2010-06-08 2017-06-30 基因泰克公司 Cysteine engineered antibody and conjugate
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 Utilize framework signature peptide to detect the multiple reaction monitoring LC-MS/MS method of the therapeutic antibodies in animal sample
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
MX2014003698A (en) 2011-09-30 2014-07-28 Genentech Inc Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells.
CA2850371C (en) 2011-10-14 2020-06-30 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2703151T3 (en) 2012-10-12 2019-03-07 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
BR112015008238A2 (en) 2012-10-12 2017-11-28 Adc Therapeutics Sarl pyrrolbenzodiazepine-anti-cd22 antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
CN109134599A (en) 2012-10-12 2019-01-04 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
EP2926142B2 (en) 2012-11-30 2022-07-06 F. Hoffmann-La Roche AG Identification of patients in need of pd-l1 inhibitor cotherapy
MX364330B (en) 2013-03-13 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
MX363787B (en) 2013-03-13 2019-04-03 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
JP6444902B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
PE20161394A1 (en) 2013-12-16 2017-01-06 Genentech Inc PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
CN105828840B (en) 2013-12-16 2020-08-04 基因泰克公司 1- (chloromethyl) -2, 3-dihydro-1H-benzo [ e ] indole dimer antibody-drug conjugate compounds and methods of use and treatment
MX371092B (en) 2013-12-16 2020-01-16 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (en) 2014-09-12 2017-05-12 Genentech Inc Cysteine engineered antibodies and conjugates.
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6752204B2 (en) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド Quadruple amine compounds and their antibodies-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplex Total Antibody and Antibody Conjugated Drug Quantification Assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (en) 2016-08-11 2024-04-05 基因泰克公司 Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
HRP20210979T1 (en) 2017-02-08 2021-09-17 Adc Therapeutics Sa PYROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
MX2019012464A (en) 2017-04-20 2019-12-11 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate.
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
HRP20220311T1 (en) 2017-08-18 2022-05-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
JP2020534300A (en) 2017-09-20 2020-11-26 ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． Tyranstatin analog
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR20210139270A (en) 2019-03-15 2021-11-22 메드임뮨 리미티드 Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102532A1 (en) * 2000-10-03 2002-08-01 Meena Augustus Cancer gene determination and therapeutic screening using signature gene sets

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
CA2512536A1 (en) 2004-07-29
WO2004063709A2 (en) 2004-07-29
EP1597558A2 (en) 2005-11-23
JP2007520995A (en) 2007-08-02
WO2004063709A3 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2004063709A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2007025044A8 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
WO2005094332A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2008144345A3 (en) Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2005067667A3 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
MX2010003438A (en) Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators.
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
AU2002361024A1 (en) Method and device for determining a light transport parameter in a biological matrix
WO2006110865A3 (en) Systems and methods for validating a security feature of an object
AU2003257207A1 (en) Use of biomarkers for detecting ovarian cancer
WO2003056314A3 (en) Analysis system for determining an analyte concentration, taking into consideration sample- and analyte-independent light-intensity changes
WO2008063414A3 (en) Gene expression profiling for identification, monitoring, and treatment of colorectal cancer
WO2006116569A3 (en) Systems and methods for correcting optical reflectance measurements
DE60020119D1 (en) Method and device for investigating drug candidates and for determining their pharmacokinetic parameters
HK1052219A1 (en) Method and apparatus for detecting the presence of a fluid on a test strip
EP1205753A3 (en) Multiplex sensor and method of use
WO2010006048A3 (en) Gene expression profiling for predicting the survivability of prostate cancer subjects
WO2007028005A3 (en) Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
DE60129151D1 (en) METHOD FOR DETECTING EGG CANCER BY MEANS OF HUMAN CALLIQUE (HK6)
AU4299800A (en) Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample
WO2003091695A3 (en) Identification of biomarkers for detecting prostate cancer
WO2003076896A3 (en) Use of biomarkers to detect breast cancer
WO2009082533A3 (en) Method of identification of petroleum compounds using frequency mixing on surfaces
WO2003098397A3 (en) Method and apparatus for determining layer thickness and composition using ellipsometric evaluation
WO2008127526A3 (en) Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2004 ADD "DECLARATION UNDER RULE 4.17: - AS TO THE APPLICANT'S ENTITLEMENT TO CLAIM THE PRIORITY OF THE EARLIER APPLICATION (RULE 4.17(III)) FOR ALL DESIGNATIONS."

WWE Wipo information: entry into national phase

Ref document number: 2512536

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004700860

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006500841

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 2004700860

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006234237

Country of ref document: US

Ref document number: 10541749

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: CR2006-008369

Country of ref document: CR

WWP Wipo information: published in national office

Ref document number: 10541749

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)